Dr Chiang
Module 1: Biology of Small-Cell Lung Cancer (SCLC) and Review of Its Initial Management
Kim SY et al. Small cell lung cancer: A review. JAMA 2025;[Online ahead of print]. Abstract
Liu SV et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 2021;39(6):619-30. Abstract
Paz-Ares LG et al. Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study. ESMO 2021;Abstract LBA61.
Spigel DR et al. ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). ASCO 2024;Abstract LBA5.
Module 2: Current Role of Tarlatamab in Therapy for SCLC
Ahn M-J et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 2023;389(22):2063-75. Abstract
Chiang AC et al. Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy. ESMO Open 2025;10(4):104538. Abstract
Chiang AC et al. Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1. ESMO Immuno-Oncology 2024;Abstract 155P.
Owen DH et al. DLL3: An emerging target in small cell lung cancer. J Hematol Oncol 2019;12(1):61. Abstract
Subbiah V et al. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer 2020;150:90-6. Abstract
Trigo J et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial. Lancet Oncol 2020;21(5):645-54. Abstract
Dr Schenk
Module 3: Future Directions in the Management of SCLC
Beltran H et al. Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC). ASCO 2024;Abstract 8090.
Bragasin EI et al. Advances in adoptive cell therapies in small cell lung cancer. Explor Target Antitumor Ther 2025;6:1002302. Abstract
Chen Y et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med 2024;391(14):1313-27. Abstract
Hummel H et al. Tarlatamab after chemoradiotherapy in limited-stage small cell lung cancer (LS-SCLC): DeLLphi-306 (NCT06117774). European Lung Cancer Congress 2024;Abstract 214TiP.
Meng Y et al. Antibody-drug conjugates treatment of small cell lung cancer: Advances in clinical research. Discov Oncol 2024;15(1):327. Abstract
Paz-Ares LG et al. Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304). ASCO 2023;Abstract TPS8611.
Rudin CM et al. Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): Interim analysis of Ideate-lung01. WCLC 2024;Abstract OA04.03.
Rudin CM et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol 2023;16(1):66. Abstract
Wermke M et al. Phase I trial of the delta-like ligand-3 (DLL3)/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive tumors: Updated data. ESMO 2024;Abstract 670P.
Module 4: Unique Considerations in SCLC Management
Chow R et al. Management of malignant superior vena cava syndrome. Ann Palliat Med 2024;13(3):620-6. Abstract
Lukas RV et al. State-of-the-art considerations in small cell lung cancer brain metastases. Oncotarget 2017;8(41):71223. Abstract
Slotman B et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357(7):664-72. Abstract
Soomro Z et al. Paraneoplastic syndromes in small cell lung cancer. J Thorac Dis 2020;12(10):6253-63. Abstract
Zeng H et al. Risk factors for brain metastases in patients with small cell lung cancer: A systematic review and meta-analysis. Front Oncol 2022;12:889161. Abstract
Ms Sandy
Module 4
Ahn M-J et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 2023;389(22):2063-75. Abstract